biotech startups
3 statements across 3 episodes · 0 bullish · 1 bearish · 2 people on the record · first statement Sep 13, 2017 by Elizabeth Iorns · across every show →
Everything said about biotech startups, oldest first
Sep 13, 2017 neutral
Iorns: Pharma companies source innovation primarily by buying clinical-stage biotechs
“The pharma companies are desperate for buying in innovation, and so they're really looking for companies to get to that initial proof of concept in a human, in human studies. So that, that's really where a lot of their innovation is coming from, is biotechs th…”
Mar 7, 2018 neutral
Buchheit: Biotech risk is technical feasibility, not market demand
“The risk on those companies is, is, is most often not market risk. It's not the risk that no one wants a cure for cancer. The risk is that they don't actually have a cure for cancer, right? So, so with those companies, more often, it's one of these things wher…”
Oct 3, 2018 negative
Iorns: Biotech spinouts rely too much on figurehead principal investigators for funding
“I think that's still very difficult for scientists, particularly PhD and postdoc scientists, so they actually make the discoveries in these labs, so they're the ones doing the work but a lot of the time for them to actually be the ones to be the founder of the…”